ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 464

Rituximab for Treatment of Rheumatoid Arthritis:  Treatment Effectiveness in the Corrona Database

Leslie R. Harrold1, George W. Reed1, Robert P. Magner1, Katherine C. Saunders2, Jeffrey D. Greenberg3, Joel M. Kremer4, Ani John5, William Reiss5, Steve Zlotnick6 and Ashwini Shewade5, 1University of Massachusetts Medical School, Worcester, MA, 2Corrona, LLC., Southborough, MA, 3New York Hospital for Joint Disease, New York, NY, 4Center for Rheumatology, Albany Medical College, Albany, NY, 5Genentech Inc., South San Francisco, CA, 6Genentech, Inc., a Member of the Roche Group, South San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Treatment options

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rituximab (RTX) in combination with methotrexate is used for the treatment of adult RA with an inadequate response to TNF antagonists. We aimed to describe the real-world use and effectiveness of RTX in a large cohort of patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) registry.

Methods: All patients with RTX initiations in CORRONA between Feb 2006 and May 2011, with available clinical disease activity index (CDAI) score at baseline and at 12-months and not in remission (CDAI ≤2.8) at the time of RTX initiation, were included. Demographic and disease characteristics at baseline; change in CDAI at 12 months (overall and based on number of prior TNFs); and reported safety events were summarized.

Results: Overall, 615 patients (mean 2.3 previous non-biologic disease-modifying anti-rheumatic drugs [DMARDs] and 2.2 prior biologic DMARDS) initiated RTX. Lack of efficacy was most commonly (65%) reported reason for discontinuing prior biologic. Of these, 265 patients (80% female; median age 57 years; median disease duration 13 years) met the inclusion criteria. Approximately 43% of the patients had received 1 prior TNF and 57% had ≥2 prior TNFs. Approximately 77% patients started RTX in combination with DMARDs and 42% with concomitant prednisone. Mean change in CDAI was -8.1 (95% CI: -9.8; -6.4) for all RTX initiators not in remission, with similar results when stratified by number of prior TNFs. Among the subset of patients with active disease (moderate/high disease activity; CDAI >10) at baseline (Table), 8% went into remission and 29% achieved low disease activity (LDA). The mean change in CDAI in these patients was -10.3 (95% CI: -12.3; -8.4) with similar results when stratified by 1 or ≥2 prior TNFs. However, more patients with 1 prior TNF went into remission or achieved LDA versus patients with ≥2 prior TNFs. Patients with 1 prior TNF were more likely to achieve remission or LDA (unadjusted odds ratio 0.40 [95% CI: 0.22; 0.73]). Among patients who started RTX with concomitant prednisone, 43% decreased and 26% had no change in their prednisone dose at 12 months. Reported rates of all cardiovascular events, serious infections, and malignancies were 1.9 (95% CI: 0.6; 4.0), 1.6 (95% CI: 0.5; 4.9), and 1.5 (95% CI: 0.6; 4.0) per 100 person-years, respectively.

Change in disease activity in patients with moderate/high disease (CDAI >10) at baseline
CDAI at 12-months All RTX initiators
(n=218)
IR to 1 prior TNF
(n=87)
IR to ≥2 prior TNFs
(n=131)
Remission (CDAI ≤2.8)
(n, %)
18 (8.3) 9 (10.3) 9 (6.9)
Low disease activity (2.8(n, %) 64 (29.4) 35 (40.2) 29 (22.1)
Mean change in CDAI (95% CI) -10.3 (-12.2; -8.4) -10.1 (-13.2; -7.0) -10.5 (-12.9; -8.0)

Conclusion: RTX appeared effective in usual care in patients with previous exposure to one or more prior TNFs, with a safety profile comparable to randomized controlled trials of RTX. More patients with 1 prior TNF versus ≥2 prior TNFs appeared to achieve improvement in disease activity at 12 months after initiating RTX. The magnitude of response in CDAI seemed to be similar regardless of number of prior TNFs, even with ≥2 prior TNFs, suggesting good response in more refractory RA patients.

CDAI = clinical disease activity index; CI = confidence interval; TNF = tumor necrosis factor-α antagonist.


Disclosure:

L. R. Harrold,

NIH-K23AR053856,

2,

Corrona,

5;

G. W. Reed,

Corrona,

2,

University of Massachusetts Medical School,

3,

Corrona,

5,

Harvard Medical School,

;

R. P. Magner,
None;

K. C. Saunders,

Corrona,

3;

J. D. Greenberg,

Corrona,

1,

AstraZeneca, Novartis, Pfizer, CORRONA,

5;

J. M. Kremer,

Genentech, Pfizer, HGS, UCB, BMS,

2,

Genentech, Pfizer, Abbott, Amgen,

5,

BMS, Pfizer, Genentech, Abbott,

8;

A. John,

Genentech,

3;

W. Reiss,

Genentech,

3;

S. Zlotnick,

Genentech,

1,

Genentech,

3;

A. Shewade,

Genentech,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-for-treatment-of-rheumatoid-arthritis-treatment-effectiveness-in-the-corrona-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology